Why Versigent (VGNT) Is On Investors’ Radar Today

Versigent (VGNT) has drawn fresh attention after recent trading, with the stock last closing at $37.50 and showing double digit returns over the past week and month.

The recent 1-day share price return of 3.7% and 30-day share price return of 33.5%, on top of a 24.2% year to date share price return, point to momentum building rather than fading for Versigent.

If you are looking for other ideas while Versigent is in focus, it could be a good moment to broaden your search and uncover 19 top founder-led companies

With shares at $37.50, a value score of 4, revenue of $8,818 and net income of $528, the question is simple: is Versigent still undervalued, or is the market already pricing in future growth?

Price-to-Earnings of 5x: Is it justified?

On a P/E of 5x, Versigent looks inexpensive compared to similar auto components companies, which are trading on an average P/E of 18.5x and an industry average of 18.9x, even with the stock at $37.50.

The P/E ratio compares the share price to earnings per share, so a lower P/E often suggests the market is placing a lower value on each dollar of current earnings. For a business with $8,818 in revenue, $528 in net income and high quality earnings, a 5x P/E implies investors are cautious about how durable those earnings will be.

Versigent’s current net profit margin of 6%, higher than last year’s 4.9%, and a high Return on Equity of 29.5% indicate the business is currently generating solid profitability on its capital. Yet, forecasts point to relatively modest annual revenue growth of 3.3% and earnings growth of 0.07%, both slower than the wider US market, which may help explain why the market is not assigning a richer multiple even with earnings having grown 29.4% over the past year.

Against the US Auto Components industry average P/E of 18.9x, Versigent’s 5x multiple stands out as much lower. This gap signals the stock is being valued far more conservatively than many peers. With insufficient data to calculate a fair P/E ratio using the SWS fair ratio model, there is no regression based reference level that the current P/E could move toward, so any comparison rests squarely on the peer and industry benchmarks already available.

Result: Price-to-Earnings of 5x (UNDERVALUED)

However, you also need to weigh risks such as relatively modest 3.3% revenue growth and any shift in auto or EV demand that could pressure a 5x P/E.

Another View: DCF Points To A Very Different Price

While the 5x P/E hints at a cheap stock, the SWS DCF model paints an even stronger picture. It puts Versigent’s future cash flow value at $165.83 per share versus the current $37.50. Trading roughly 77% below that estimate, is this a genuine opportunity or a sign that assumptions are too optimistic?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Versigent for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Curious whether this optimism outweighs the concerns or the other way around? Take a closer look at the data and form your own view with 2 key rewards and 1 important warning sign

Looking for more investment ideas?

Once you have formed a view on Versigent, do not stop there. Broader ideas can help you spot opportunities you might otherwise miss.

• Target reliable income by assessing companies with higher yields and resilient payouts through the 1 dividend fortresses.
• Hunt for potential bargains trading below their assessed value with the help of the 51 high quality undervalued stocks.
• Strengthen your watchlist with companies that pair financial stability and healthy fundamentals using the solid balance sheet and fundamentals stocks screener (46 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.